How are margins trending for Merit Medical (MMSI)?

Q2 2026 GAAP gross margin was 51.4% versus 48.2% a year ago, and non-GAAP gross margin was 55.8% versus 53.2%. GAAP operating margin improved to 14.4%, while non-GAAP operating margin increased to 22.6%, up from 21.2%.

Merit Medical (NASDAQ: MMSI) boosts 2026 outlook after strong Q2 results

Q: How did Merit Medical (MMSI) perform in Q2 2026?

Merit Medical reported Q2 2026 net sales of $418.843 million , up 10% year-over-year, with 9% constant currency growth. GAAP EPS was $0.65 and non-GAAP EPS was $1.19 , supported by higher gross and operating margins.

Q: What guidance did Merit Medical (MMSI) provide for full-year 2026?

For 2026, Merit expects revenue of $1.631–$1.643 billion , implying 7.6–8.4% growth, and non-GAAP EPS of $4.25–$4.35 , implying 11–14% growth. Both revenue and EPS ranges were raised from the prior April 2026 guidance.

Q: What is Merit Medical’s (MMSI) cash and debt position as of June 30, 2026?

As of June 30, 2026, Merit held $448.7 million in cash and cash equivalents and had $747.5 million in total debt obligations. The company also reported approximately $697 million of available borrowing capacity under its facilities.

Q: How does Merit Medical (MMSI) use non-GAAP financial measures?

Merit supplements GAAP results with non-GAAP metrics such as non-GAAP gross margin, operating margin, net income, EPS, constant currency revenue, and free cash flow. These exclude items like acquisition-related amortization, restructuring, certain litigation costs, and other non-core or infrequent items.

Q: What drove Merit Medical’s (MMSI) revenue growth by category in Q2 2026?

In Q2 2026, total revenue grew 10% . Foundational products increased 7% , while Therapeutic products rose 15% . Within Therapeutic, Cardiac Therapies, Endoscopy, and OEM each posted double-digit growth, with Endoscopy up 29% year-over-year on a reported basis.

Q: How did acquisitions and divestitures affect Merit Medical’s (MMSI) organic growth?

Merit’s constant currency revenue, organic adjusts for acquisitions and the DualCap divestiture. For Q2 2026, organic constant currency revenue growth was highlighted at 9% , excluding revenue from recent deals and the DualCap product line sold in February 2026.

Filing Impact

(High)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Merit Medical Systems, Inc. reported strong second-quarter 2026 results, with net sales of $418.843 million, up 10% year-over-year and 9% on a constant currency basis. Management highlighted 9% organic, constant currency revenue growth excluding a strategic divestiture and 10% growth in U.S. sales. GAAP gross margin improved to 51.4% and non-GAAP gross margin to 55.8%. GAAP net income was $38.8 million ($0.65 per diluted share), while non-GAAP net income was $71.3 million ($1.19 per share), an 18% year-over-year increase.

GAAP operating margin rose to 14.4% and non-GAAP operating margin to 22.6%. For the first six months, free cash flow was $76.6 million. As of June 30, 2026, the company held $448.7 million in cash and cash equivalents, total debt obligations of $747.5 million, and approximately $697 million of available borrowing capacity.

Merit raised its full-year 2026 outlook, now guiding total revenue to $1.631–$1.643 billion (7.6–8.4% growth) and non-GAAP earnings per share to $4.25–$4.35, implying 11–14% growth, compared with prior EPS guidance of $4.01–$4.15. Management continues to target its three-year Continued Growth Initiative financial objectives through 2026.

Positive

Non-GAAP EPS rose 18% year-over-year to $1.19 in Q2 2026, with net sales up 10% and both GAAP and non-GAAP margins expanding.
Full-year 2026 non-GAAP EPS guidance increased to $4.25–$4.35 (expected growth 11–14%) and revenue guidance to $1.631–$1.643 billion, above the prior outlook.

Negative

None.

Filing Explained

Forward non-GAAP EPS includes $0.03 per share of convertible-note dilution, while capped-call offsets are excluded from the calculation.

This Form 8-K reports the company’s second-quarter results and updated 2026 guidance under Items 2.02 and 7.01; those materials are furnished, and the filing says they are not deemed filed for Section 18 purposes.

The guidance is an estimate based on information available on July 30, 2026, and excludes potential effects from trade policies, material acquisitions, non-recurring transactions, and other factors beyond current expectations.

For existing common holders, forward non-GAAP EPS includes $0.03 per share of dilutive impact from the 3.00% convertible senior notes due 2029, using the if-converted method; associated capped-call offsets are excluded.

The next resolution point is the year ending December 31, 2026, when actual results can be compared with the stated guidance, which the company says could vary materially if its assumptions or risk conditions change.

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Q2 2026 Net Sales: 418,843 (in thousands) Q2 2026 GAAP Gross Margin: 51.4% Q2 2026 Non-GAAP Gross Margin: 55.8% +5 more

8 metrics

Q2 2026 Net Sales 418,843 (in thousands) Net sales for the three months ended June 30, 2026; up 10% year-over-year

Q2 2026 GAAP Gross Margin 51.4% GAAP gross margin for the second quarter of 2026

Q2 2026 Non-GAAP Gross Margin 55.8% Non-GAAP gross margin for the second quarter of 2026

Q2 2026 GAAP Net Income $38.8 million GAAP net income for the three months ended June 30, 2026

Q2 2026 Non-GAAP Net Income $71.3 million Non-GAAP net income for the three months ended June 30, 2026

Q2 2026 Non-GAAP EPS $1.19 Non-GAAP earnings per diluted share for the second quarter of 2026

2026 Revenue Guidance $1.631–$1.643 billion Updated total revenue guidance for year ending December 31, 2026

2026 Non-GAAP EPS Guidance $4.25–$4.35 Updated non-GAAP earnings per share guidance for full-year 2026

Key Terms

constant currency revenue, non-GAAP operating margin, free cash flow, Convertible Senior Notes, +1 more

5 terms

constant currency revenue financial

"The constant currency revenue adjustment of $(3.0) million and $(10.9) million"

Revenue reported after removing the impact of changes in foreign exchange rates, so sales from overseas operations are measured using the same exchange rates as in a prior period. It matters to investors because it isolates a company's underlying sales performance from currency swings—like comparing two years using the same ruler—making it easier to see whether growth comes from business momentum or simply from favorable exchange-rate moves.

non-GAAP operating margin financial

"Non-GAAP operating margin* was 22.6%, compared to 21.2%"

Non-GAAP operating margin is a way companies show how much profit they make from their main business activities, excluding certain expenses or income they consider unusual or non-recurring. It helps investors see how well the company is performing in its normal operations, without the effects of one-time costs or gains that might distort the picture.

free cash flow financial

"Free cash flow is defined as cash flow from operations... less capital expenditures"

Free cash flow is the amount of money a company has left over after paying all its expenses and investing in its business, like buying equipment or updating facilities. It shows how much cash is available to reward shareholders, pay down debt, or save for future growth. This helps investors understand if a company is financially healthy and able to grow.

Convertible Senior Notes financial

"3.00% Convertible Senior Notes due 2029 (the “Convertible Notes”)"

Convertible senior notes are a type of loan that a company issues to investors, which can be turned into company shares later on. They are called "senior" because they are paid back before other debts if the company runs into trouble. This allows investors to earn interest like a loan but also have the chance to own part of the company if its value rises.

Medical Device Regulation expenses regulatory

"Medical Device Regulation expenses (c)"

Earnings Snapshot

Net sales: 418,843 (in thousands) · Guidance included

Three and six months ended June 30, 2026

Net sales 418,843 (in thousands) up 10% vs Q2 2025 on a reported basis

GAAP diluted EPS $0.65 up from $0.54 in Q2 2025

Non-GAAP EPS $1.19 up 18% vs Q2 2025

Non-GAAP operating margin 22.6% up from 21.2% in Q2 2025

Guidance

For 2026, Merit forecasts revenue of $1.631–$1.643 billion (7.6–8.4% growth) and non-GAAP EPS of $4.25–$4.35, implying 11–14% year-over-year growth and exceeding prior April 2026 guidance ranges.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Available on EDGAR 07/30/2026 - 04:14 PM Accepted by SEC EDGAR 07/30/2026 - 04:13 PM

FAQ

How did Merit Medical (MMSI) perform in Q2 2026?

Merit Medical reported Q2 2026 net sales of $418.843 million, up 10% year-over-year, with 9% constant currency growth. GAAP EPS was $0.65 and non-GAAP EPS was $1.19, supported by higher gross and operating margins.

What guidance did Merit Medical (MMSI) provide for full-year 2026?

For 2026, Merit expects revenue of $1.631–$1.643 billion, implying 7.6–8.4% growth, and non-GAAP EPS of $4.25–$4.35, implying 11–14% growth. Both revenue and EPS ranges were raised from the prior April 2026 guidance.

What is Merit Medical’s (MMSI) cash and debt position as of June 30, 2026?

As of June 30, 2026, Merit held $448.7 million in cash and cash equivalents and had $747.5 million in total debt obligations. The company also reported approximately $697 million of available borrowing capacity under its facilities.

How does Merit Medical (MMSI) use non-GAAP financial measures?

Merit supplements GAAP results with non-GAAP metrics such as non-GAAP gross margin, operating margin, net income, EPS, constant currency revenue, and free cash flow. These exclude items like acquisition-related amortization, restructuring, certain litigation costs, and other non-core or infrequent items.

What drove Merit Medical’s (MMSI) revenue growth by category in Q2 2026?

In Q2 2026, total revenue grew 10%. Foundational products increased 7%, while Therapeutic products rose 15%. Within Therapeutic, Cardiac Therapies, Endoscopy, and OEM each posted double-digit growth, with Endoscopy up 29% year-over-year on a reported basis.

How did acquisitions and divestitures affect Merit Medical’s (MMSI) organic growth?

Merit’s constant currency revenue, organic adjusts for acquisitions and the DualCap divestiture. For Q2 2026, organic constant currency revenue growth was highlighted at 9%, excluding revenue from recent deals and the DualCap product line sold in February 2026.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): July 30, 2026

Merit Medical Systems, Inc.

(Exact name of registrant as specified in its charter)


Utah	0-18592	87-0447695
(State or other jurisdiction of	(Commission	(I.R.S. Employer
incorporation or organization)	File Number)	Identification No.)


1600 West Merit Parkway
South Jordan, Utah		84095
(Address of principal executive offices)		(Zip Code)

(801) 253-1600

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, no par value		MMSI		NASDAQ Global Select Market System

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On July 30, 2026, Merit Medical Systems, Inc. (“Merit”) issued a press release announcing its operating and financial results for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

On July 30, 2026, Merit is conducting a conference call to discuss its operating and financial results for the quarter ended June 30, 2026. A live webcast and conference call presentation will also be available for the conference call at merit.com. A copy of the conference call presentation is furnished as Exhibit 99.2 to this report and incorporated herein by reference.

The information contained in Item 2.02 and Item 7.01 of this report (including the exhibits attached hereto) is furnished pursuant to General Instruction B.2. of Form 8-K and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by Merit under the Securities Act of 1933, as amended, or the Exchange Act.

In addition to disclosing results that are determined in accordance with Generally Accepted Accounting Principles (“GAAP”), Merit is disclosing non-GAAP financial information in both the press release announcing its operating and financial results and the conference call presentation. Reconciliations of certain of these non-GAAP financial measures to the comparable GAAP financial measures are included in the press release and conference call presentation attached as Exhibit 99.1 and 99.2 to this report, respectively. Merit does not provide guidance for GAAP reported financial measures (other than revenue) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures (other than revenue) because Merit is unable to predict with reasonable certainty the financial impact of items such as expenses related to acquisitions or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain severance expenses, performance-based stock compensation expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings, and changes in governmental or industry regulations. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For the same reasons, Merit is unable to address the significance of the unavailable information, which could be material to future results. Specifically, Merit is not, without unreasonable effort, able to reasonably predict the amount and impact of these items and Merit believes inclusion of the most directly comparable GAAP financial measure, and a reconciliation of these forward-looking non-GAAP figures to their GAAP counterparts, could be confusing to investors or cause undue reliance.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits


EXHIBIT NUMBER		DESCRIPTION

99.1		Press Release, dated July 30, 2026, entitled “Merit Medical Reports Second Quarter 2026 Results and Updates Full-Year 2026 Guidance” including unaudited financial information.
99.2		Conference Call Presentation
104		The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MERIT MEDICAL SYSTEMS, INC.


Date: July 30, 2026	By:	/s/ Brian G. Lloyd
		Brian G. Lloyd
		Chief Legal Officer and Corporate Secretary

Exhibit 99.1


	Contacts:
	PR/Media Inquiries: Sarah Comstock Merit Medical	Investor Inquiries: Mike Piccinino, CFA, IRC ICR Healthcare
	+1-801-432-2864	+1-443-213-0509
	sarah.comstock@merit.com	mike.piccinino@icrhealthcare.com

FOR IMMEDIATE RELEASE

MERIT MEDICAL REPORTS SECOND QUARTER 2026 RESULTS AND UPDATES FULL-YEAR 2026 GUIDANCE

Financial Highlights†

●

Reported revenue of $418.8 million, up 10%

●

Constant currency revenue* and constant currency revenue, organic* up 9% and up 9%, respectively

●

GAAP operating margin of 14.4%, compared to 12.3% in prior year period

●

Non-GAAP operating margin* of 22.6%, compared to 21.2% in prior year period

●

GAAP EPS $0.65, up 20%

●

Non-GAAP EPS* $1.19, up 18%

●

Cash flow from operations of $110.0 million year-to-date, down 11%

●

Free cash flow* generation of $76.6 million year-to-date, down 14%

† Comparisons above are calculated for the current quarter compared with the second quarter of 2025, unless otherwise specified. Amounts stated in this release are rounded, while percentages are calculated from the underlying amounts.

* Constant currency revenue; constant currency revenue, organic; non-GAAP gross profit and margin; non-GAAP operating income and margin; non-GAAP net income; non-GAAP EPS; and free cash flow figures (used here and below) are non-GAAP financial measures. A reconciliation of these financial measures to their most directly comparable GAAP financial measures is included under the heading “Non-GAAP Financial Measures” below.

SOUTH JORDAN, Utah, July 30, 2026 -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced financial results for the three and six-month periods ended June 30, 2026.

“Merit delivered second quarter financial results that exceeded the high end of our expectations, driven primarily by 9% organic, constant currency revenue growth, excluding the impact of a strategic divestiture,” said Martha G. Aronson, Merit’s President and CEO. “We experienced improving revenue growth trends across our global business in Q2, as expected, with notable strength in sales to customers in the U.S. which increased 10% year-over-year, well ahead of our expectations. We also delivered improvement in both our non-GAAP operating margin and our non-GAAP earnings per share, which increased by 140 basis points and 18%, respectively, year-over-year.”

Ms. Aronson continued: “We have increased our 2026 revenue and non-GAAP earnings per share guidance to reflect the stronger-than-expected results over the first half of 2026 and remain confident in our team’s ability to execute, with attractive constant currency growth, improving profitability, and solid cash flow generation this year. Our team remains focused on delivering our Continued Growth Initiative financial targets for the three-year period ending December 31, 2026, and, in parallel, we are developing our longer-term strategic plan focused on identifying opportunities to better position the company for sustainable growth, enhanced profitability and value creation for our shareholders.”

Merit’s revenue by product category for the three and six-month periods ended June 30, 2026 and 2025 was as follows (unaudited; in thousands, except for percentages):


		Three Months Ended
		Reported									Constant Currency*
		June 30,							Impact of foreign		June 30,
		2026			2025		% Change		exchange		2026		% Change
Foundational
Access		$	161,786		$	152,122	6	%	$	(2,340)	$	159,446	5	%
OEM			48,338			43,218	12	%		(29)		48,309	12	%
Procedural Solutions			27,949			31,741	(12)	%		140		28,089	(12)	%
Vascular Intervention			41,652			34,955	19	%		(409)		41,243	18	%
Other			1,236			346	257	%		1,102		2,338	576	%
Total Foundational			280,961			262,382	7	%		(1,536)		279,425	6	%

Therapeutic
Cardiac Therapies			28,510			22,930	24	%		(479)		28,031	22	%
Endoscopy			23,647			18,400	29	%		37		23,684	29	%
OEM			12,797			9,735	31	%		(20)		12,777	31	%
Oncology			25,774			23,943	8	%		(171)		25,603	7	%
Renal Therapies			12,713			12,817	(1)	%		(164)		12,549	(2)	%
Vascular Intervention			34,441			32,255	7	%		(654)		33,787	5	%
Total Therapeutic			137,882			120,080	15	%		(1,451)		136,431	14	%

Total		$	418,843		$	382,462	10	%	$	(2,987)	$	415,856	9	%


		Six Months Ended
		Reported									Constant Currency *
		June 30,							Impact of foreign		June 30,
		2026			2025		% Change		exchange		2026		% Change
Foundational
Access		$	312,910		$	286,520	9	%	$	(7,520)	$	305,390	7	%
OEM			87,878			86,641	1	%		(264)		87,614	1	%
Procedural Solutions			54,437			60,310	(10)	%		(18)		54,419	(10)	%
Vascular Intervention			80,690			67,804	19	%		(1,472)		79,218	17	%
Other			525			1,489	(65)	%		2,749		3,274	120	%
Total Foundational			536,440			502,764	7	%		(6,525)		529,915	5	%

Therapeutic
Cardiac Therapies			55,914			43,489	29	%		(1,694)		54,220	25	%
Endoscopy			45,339			34,951	30	%		20		45,359	30	%
OEM			20,276			20,877	(3)	%		(50)		20,226	(3)	%
Oncology			49,282			45,994	7	%		(526)		48,756	6	%
Renal Therapies			24,225			26,206	(8)	%		(392)		23,833	(9)	%
Vascular Intervention			69,244			63,532	9	%		(1,756)		67,488	6	%
Total Therapeutic			264,280			235,049	12	%		(4,398)		259,882	11	%

Total		$	800,720		$	737,813	9	%	$	(10,923)	$	789,797	7	%

Financial Summary:

GAAP gross margin was 51.4%, compared to 48.2% for the second quarter of 2025. Non-GAAP gross margin* was 55.8%, compared to 53.2% for the second quarter of 2025.

GAAP operating margin was 14.4%, compared to 12.3% for the second quarter of 2025. Non-GAAP operating margin* was 22.6%, compared to 21.2% for the second quarter of 2025.

GAAP net income was $38.8 million, or $0.65 per share, compared to $32.6 million, or $0.54 per share, for the second quarter of 2025. Non-GAAP net income* was $71.3 million, or $1.19 per share, compared to $61.0 million, or $1.01 per share, for the second quarter of 2025.

As of June 30, 2026, Merit had cash and cash equivalents of $448.7 million and total debt obligations of $747.5 million, compared to cash and cash equivalents of $446.4 million and total debt obligations of $747.5 million as of December 31, 2025. Merit had available borrowing capacity of approximately $697 million as of June 30, 2026.

Fiscal Year 2026 Financial Guidance

Based upon the information currently available to Merit’s management, for the twelve-month period ending December 31, 2026, absent the potential impact of trade policies and related actions implemented by the U.S. and other countries subsequent to today’s date, material acquisitions, non-recurring transactions or other factors beyond Merit’s current expectations, Merit anticipates the following financial results:

Revenue and Earnings Guidance*


		Updated Guidance		Prior Guidance⁽²⁾
		Year Ending	% Change	Year Ending	% Change
Financial Measure		December 31, 2026	Y/Y	December 31, 2026	Y/Y
Total Revenue		$1.631 - $1.643 billion	8% - 8%	$1.612 - $1.634 billion	6% - 8%

Non-GAAP Earnings Per Share⁽¹⁾		$4.25 - $4.35	11% - 14%	$4.01 - $4.15	5% - 8%

*Percentage figures approximated; dollar figures may not foot due to rounding.

(1) Merit’s non-GAAP earnings per share reflect the dilutive impact of its 3.00% Convertible Senior Notes due 2029 (the “Convertible Notes”) calculated using the if-converted method of approximately $0.03 per share for the year ending December 31, 2026. Any offsetting impacts of the capped call associated with the Convertible Notes are not considered.

(2) “Prior Guidance” reflects Merit’s full-year 2026 financial guidance, previously introduced on April 30, 2026.

Merit does not provide guidance for GAAP reported financial measures (other than revenue) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures (other than revenue) because Merit is unable to predict with reasonable certainty the financial impact of various items which could impact Merit’s future financial results, such as expenses attributable to acquisitions or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain employee termination benefits, performance-based stock compensation expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings, and changes in governmental or industry regulations. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For the same reasons, Merit is unable to address the significance of the unavailable information, which could be material to future results. Specifically, Merit is not, without unreasonable effort, able to reasonably predict the amount and impact of these items and Merit believes inclusion of the most comparable GAAP financial measure, and a reconciliation of these forward-looking non-GAAP measures to their GAAP counterparts could be confusing to investors or cause undue reliance.

Merit’s financial guidance for the year ending December 31, 2026 is subject to risks and uncertainties identified in this release and Merit’s filings with the SEC. This guidance is based on information and estimates available to Merit as of July 30, 2026. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results will likely vary, and could vary materially, from past results and those anticipated, estimated or projected.

CONFERENCE CALL

As previously announced, Merit will hold its investor conference call today, Thursday, July 30, 2026, at 4:30 p.m., Eastern Time, to discuss its results for the second quarter and provide an operational update. To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide deck will also be available at merit.com.

CONSOLIDATED BALANCE SHEETS

(in thousands)


	June 30,		December 31,
	2026		2025
ASSETS	(Unaudited)
Current Assets
Cash and cash equivalents	$	448,699	$	446,404
Trade receivables, net		224,237		203,710
Other receivables		23,960		17,773
Inventories		374,112		333,705
Prepaid expenses and other assets		33,496		31,493
Prepaid income taxes		5,033		4,941
Income tax refund receivables		2,701		2,128
Total current assets		1,112,238		1,040,154

Property and equipment, net		436,749		428,401
Intangible assets, net		612,026		537,654
Goodwill		539,772		506,837
Deferred income tax assets		7,200		7,049
Operating lease right-of-use assets		83,776		87,600
Other assets		71,859		78,227
Total Assets	$	2,863,620	$	2,685,922

LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
Trade payables	$	70,737	$	60,551
Accrued expenses		172,185		159,486
Current operating lease liabilities		10,921		10,876
Income taxes payable		11,090		8,851
Total current liabilities		264,933		239,764

Long-term debt		736,258		734,038
Deferred income tax liabilities		39,704		19,665
Liabilities related to unrecognized tax benefits		2,248		2,248
Deferred compensation payable		19,297		17,542
Deferred credits		1,347		1,398
Long-term operating lease liabilities		72,942		76,658
Other long-term obligations		47,087		10,306
Total liabilities		1,183,816		1,101,619

Stockholders' Equity
Common stock		783,892		763,909
Retained earnings		903,828		824,030
Accumulated other comprehensive loss		(7,916)		(3,636)
Total stockholders' equity		1,679,804		1,584,303
Total Liabilities and Stockholders' Equity	$	2,863,620	$	2,685,922

CONSOLIDATED STATEMENTS OF INCOME

(Unaudited, in thousands except per share amounts)


		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2026			2025			2026			2025
Net sales		$	418,843		$	382,462		$	800,720		$	737,813
Cost of sales			203,677			197,975			400,757			381,306
Gross profit			215,166			184,487			399,963			356,507

Operating expenses:
Selling, general and administrative			129,229			113,097			247,439			220,583
Research and development			25,389			24,367			47,998			46,845
Contingent consideration expense (benefit)			145			143			(34)			1,166
Total operating expenses			154,763			137,607			295,403			268,594

Income from operations			60,403			46,880			104,560			87,913

Other income (expense):
Interest income			3,752			3,761			7,652			7,551
Interest expense			(12,118)			(6,775)			(18,644)			(13,343)
Other (expense) income — net			(723)			(487)			11,292			(784)
Total other (expense) income — net			(9,089)			(3,501)			300			(6,576)

Income before income taxes			51,314			43,379			104,860			81,337

Income tax expense			12,511			10,798			25,062			18,609

Net income		$	38,803		$	32,581		$	79,798		$	62,728

Earnings per common share
Basic		$	0.65		$	0.55		$	1.34		$	1.06
Diluted		$	0.65		$	0.54		$	1.33		$	1.03

Weighted average shares outstanding
Basic			59,679			59,140			59,595			59,019
Diluted			60,006			60,611			60,010			60,945

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited, in thousands)


		Six Months Ended
		June 30,
		2026			2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income		$	79,798		$	62,728
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization			61,538			60,313
Gain on disposition of a business			(12,557)			(249)
Amortization of right-of-use operating lease assets			5,779			5,766
Fair value adjustments related to contingent consideration liabilities			(34)			1,166
Stock-based compensation expense			21,876			19,951
Other adjustments			4,388			3,173
Changes in operating assets and liabilities, net of acquisitions and divestitures			(50,831)			(28,969)
Total adjustments			30,159			61,151
Net cash, cash equivalents, and restricted cash provided by operating activities			109,957			123,879

CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures for property and equipment			(33,340)			(34,812)
Proceeds from asset and business dispositions			25,555			294
Cash paid for notes receivable and other investments			—			(14,617)
Cash paid in acquisitions, net of cash acquired			(92,997)			(122,555)
Other investing, net			(1,617)			(1,296)
Net cash, cash equivalents, and restricted cash used in investing activities			(102,399)			(172,986)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock			4,623			20,014
Contingent payments related to acquisitions			(2,991)			(2,567)
Payment of taxes related to an exchange of common stock			(6,973)			(6,145)
Net cash, cash equivalents, and restricted cash (used in) provided by financing activities			(5,341)			11,302
Effect of exchange rates on cash			140			2,953
Net increase (decrease) in cash, cash equivalents and restricted cash			2,357			(34,852)

CASH, CASH EQUIVALENTS AND RESTRICTED CASH:
Beginning of period			448,549			378,767
End of period		$	450,906		$	343,915

RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH TO THE CONSOLIDATED BALANCE SHEETS:
Cash and cash equivalents			448,699			341,819
Restricted cash reported in prepaid expenses and other current assets			2,207			2,096
Total cash, cash equivalents and restricted cash		$	450,906		$	343,915

Non-GAAP Financial Measures

Although Merit’s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”), Merit’s management believes that the non-GAAP financial measures referenced in this release may provide investors with useful information regarding the underlying business trends and performance of Merit’s ongoing operations and can be useful for period-over-period comparisons of such operations. Non-GAAP financial measures used in this release include:

●

constant currency revenue;

●

constant currency revenue, organic;

●

non-GAAP gross profit and margin;

●

non-GAAP operating income and margin;

●

non-GAAP net income;

●

non-GAAP earnings per share; and

●

free cash flow.

Merit’s management team uses these non-GAAP financial measures to evaluate Merit’s profitability and efficiency, to compare operating and financial results to prior periods, to evaluate changes in the results of its operating segments, and to measure and allocate financial resources internally. However, Merit’s management does not consider such non-GAAP measures in isolation or as an alternative to measures determined in accordance with GAAP.

Readers should consider non-GAAP measures used in this release in addition to, not as a substitute for, financial reporting measures prepared in accordance with GAAP. These non-GAAP financial measures generally exclude some, but not all, items that may affect Merit’s net income. In addition, they are subject to inherent limitations as they reflect the exercise of judgment by management about which items are excluded. Merit believes it is useful to exclude such items in the calculation of non-GAAP gross profit and margin, non-GAAP operating income and margin, non-GAAP net income, and non-GAAP earnings per share (in each case, as further illustrated in the reconciliation tables below) because such amounts in any specific period may not directly correlate to the underlying performance of Merit’s business operations and can vary significantly between periods as a result of factors such as acquisition or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain employee termination benefits, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings or changes in tax or industry regulations, gains or losses on disposal of certain assets, equity method investment loss (income) from equity investees, and debt issuance costs. Merit may incur similar types of expenses in the future, and the non-GAAP financial information included in this release should not be viewed as a statement or indication that these types of expenses will not recur. Additionally, the non-GAAP financial measures used in this release may not be comparable with similarly titled measures of other companies. Merit urges readers to review the reconciliations of its non-GAAP financial measures to their most directly comparable GAAP financial measures included herein, and not to rely on any single financial measure to evaluate Merit’s business or results of operations.

Constant Currency Revenue

Merit’s constant currency revenue is prepared by converting the current-period reported revenue of subsidiaries whose functional currency is a currency other than the U.S. dollar at the applicable foreign exchange rates in effect during the comparable prior-year period and adjusting for the effects of hedging transactions on reported revenue, which are recorded in the U.S. dollar. The constant currency revenue adjustment of $(3.0) million and $(10.9) million to reported revenue for the three and six-month periods ended June 30, 2026 was calculated using the applicable average foreign exchange rates for the three and six-month periods ended June 30, 2025.

Constant Currency Revenue, Organic

Merit’s constant currency revenue, organic, is defined, with respect to prior fiscal year periods, as GAAP revenue less revenue from certain divestitures. For the three and six-month periods ended June 30, 2025, Merit’s constant currency revenue, organic, excludes revenues attributable to the DualCap® product line which Merit sold to Health Line International Corporation (“Health Line”) on February 17, 2026 (the “DualCap Divestiture”).

With respect to current fiscal year periods, constant currency revenue, organic, is defined as constant currency revenue (as defined above), less revenue from certain acquisitions and divestitures. For the three and six-month periods ended June 30, 2026, Merit’s constant currency revenue, organic, excludes revenues attributable to products acquired in connection with (i) Merit’s acquisition of View Point Medical, Inc. (“View Point”) in April 2026 (the “View Point Merger”), (ii) the assets acquired from Pentax of America, Inc. related to the C2 CryoBalloon™ device in November 2025 (the “C2 Acquisition”) and (iii) Merit’s acquisition of Biolife Delaware, L.L.C. (“Biolife”) in May 2025 (the “Biolife Merger”). For the six-month period ended June 30, 2026, Merit’s constant currency revenue, organic, excludes revenues attributable to the DualCap Divestiture.

Non-GAAP Gross Profit and Margin

Non-GAAP gross profit is calculated by reducing GAAP cost of sales by amounts recorded for amortization of intangible assets and inventory mark-up related to acquisitions. Non-GAAP gross margin is calculated by dividing non-GAAP gross profit by reported net sales.

Non-GAAP Operating Income and Margin

Non-GAAP operating income is calculated by adjusting GAAP operating income for certain items which are deemed by Merit’s management to be outside of core operations and vary in amount and frequency among periods, such as expenses related to acquisitions or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain employee termination benefits, performance-based stock compensation expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings, and changes in governmental or industry regulations, as well as other items referenced in the tables below. Non-GAAP operating margin is calculated by dividing non-GAAP operating income by reported net sales.

Non-GAAP Net Income

Non-GAAP net income is calculated by adjusting GAAP net income for the items set forth in the definition of non-GAAP operating income above, as well as for expenses related to Merit’s long-term debt, gains or losses on disposal of certain assets, equity method investment loss (income) from equity investees, and other items set forth in the tables below.

Non-GAAP EPS

Non-GAAP EPS is defined as non-GAAP net income divided by the diluted shares outstanding for the corresponding period.

Free Cash Flow

Free cash flow is defined as cash flow from operations calculated in accordance with GAAP, less capital expenditures for property and equipment calculated in accordance with GAAP, as set forth in the consolidated statement of cash flows.

Other Non-GAAP Financial Measure Reconciliations

The following tables set forth supplemental financial data and corresponding reconciliations of non-GAAP financial measures to Merit’s corresponding financial measures prepared in accordance with GAAP, in each case, for the three and six-month periods ended June 30, 2026 and 2025. The non-GAAP income adjustments referenced in the following tables do not reflect non-performance-based stock compensation expense of $6.3 million and $5.0 million for the three-month periods ended June 30, 2026 and 2025, respectively, and $9.5 million and $9.3 million for the six-month periods ended June 30, 2026 and 2025, respectively.

Reconciliation of GAAP Net Income to Non-GAAP Net Income

(Unaudited, in thousands except per share amounts)


	Three Months Ended
	June 30, 2026
	Pre-Tax		Tax Impact		After-Tax		Per Share Impact
GAAP net income	$	51,314	$	(12,511)	$	38,803	$	0.65

Non-GAAP adjustments:
Cost of Sales
Amortization of intangibles		18,718		(4,419)		14,299		0.24
Operating Expenses
Contingent consideration expense		145		(33)		112		0.00
Amortization of intangibles		2,496		(589)		1,907		0.03
Performance-based share-based compensation (a)		6,621		(756)		5,865		0.10
Corporate restructuring (b)		2,159		(510)		1,649		0.03
Acquisition-related		2,568		(194)		2,374		0.04
Medical Device Regulation expenses (c)		1,452		(342)		1,110		0.02
Other (Income) Expense
Long-term debt costs (e)		6,477		(1,529)		4,948		0.08
Other non-operating loss (f)		294		(82)		212		0.00

Non-GAAP net income	$	92,244	$	(20,965)	$	71,279	$	1.19

Diluted shares								60,006


	Three Months Ended
	June 30, 2025
	Pre-Tax		Tax Impact		After-Tax		Per Share Impact
GAAP net income	$	43,379	$	(10,798)	$	32,581	$	0.54

Non-GAAP adjustments:
Cost of Sales
Amortization of intangibles		18,980		(4,485)		14,495		0.24
Inventory mark-up related to acquisitions		67		(16)		51		0.00
Operating Expenses
Contingent consideration expense		143		25		168		0.00
Amortization of intangibles		2,543		(601)		1,942		0.03
Performance-based share-based compensation (a)		5,879		(345)		5,534		0.09
Corporate restructuring (b)		2,587		(611)		1,976		0.03
Acquisition-related		2,140		(14)		2,126		0.04
Medical Device Regulation expenses (c)		1,634		(385)		1,249		0.02
Other (d)		50		(12)		38		0.00
Other (Income) Expense
Long-term debt costs (e)		1,414		(334)		1,080		0.02
Gain on disposal of business unit		(249)		—		(249)		(0.00)

Non-GAAP net income	$	78,567	$	(17,576)	$	60,991	$	1.01

Diluted shares								60,611

Note: Certain per-share impacts may not sum to totals due to rounding.

Reconciliation of GAAP Net Income to Non-GAAP Net Income

(Unaudited, in thousands except per share amounts)


	Six Months Ended
	June 30, 2026
	Pre-Tax		Tax Impact		After-Tax		Per Share Impact
GAAP net income	$	104,860	$	(25,062)	$	79,798	$	1.33

Non-GAAP adjustments:
Cost of Sales
Amortization of intangibles		36,945		(8,722)		28,223		0.47
Operating Expenses
Contingent consideration benefit		(34)		5		(29)		(0.00)
Amortization of intangibles		4,950		(1,168)		3,782		0.06
Performance-based share-based compensation (a)		12,429		(1,062)		11,367		0.19
Corporate restructuring (b)		2,159		(510)		1,649		0.03
Acquisition-related		6,811		(905)		5,906		0.10
Medical Device Regulation expenses (c)		2,070		(488)		1,582		0.03
Other (Income) Expense
Long-term debt costs (e)		7,891		(1,863)		6,028		0.10
Gain on disposal of business unit		(12,502)		1,520		(10,982)		(0.18)
Other non-operating loss (f)		825		(207)		618		0.01

Non-GAAP net income	$	166,404	$	(38,462)	$	127,942	$	2.13

Diluted shares								60,010


	Six Months Ended
	June 30, 2025
	Pre-Tax		Tax Impact		After-Tax		Per Share Impact
GAAP net income	$	81,337	$	(18,609)	$	62,728	$	1.03

Non-GAAP adjustments:
Cost of Sales
Amortization of intangibles		36,586		(8,645)		27,941		0.46
Inventory mark-up related to acquisitions		67		(16)		51		0.00
Operating Expenses
Contingent consideration expense		1,166		34		1,200		0.02
Amortization of intangibles		4,937		(1,167)		3,770		0.06
Performance-based share-based compensation (a)		10,653		(931)		9,722		0.16
Corporate restructuring (b)		2,587		(611)		1,976		0.03
Acquisition-related		2,156		(18)		2,138		0.04
Medical Device Regulation expenses (c)		3,228		(762)		2,466		0.04
Other (d)		29		(7)		22		0.00
Other (Income) Expense
Long-term debt costs (e)		2,828		(668)		2,160		0.04
Gain on disposal of business unit		(249)		—		(249)		(0.00)

Non-GAAP net income	$	145,325	$	(31,400)	$	113,925	$	1.87

Diluted shares								60,945

Note: Certain per-share impacts may not sum to totals due to rounding.

Reconciliation of Reported Operating Income to Non-GAAP Operating Income

(Unaudited, in thousands except percentages)


	Three Months Ended				Three Months Ended				Six Months Ended				Six Months Ended
	June 30, 2026				June 30, 2025				June 30, 2026				June 30, 2025
	Amounts		% Sales		Amounts		% Sales		Amounts		% Sales		Amounts		% Sales
Net Sales as Reported	$	418,843			$	382,462			$	800,720			$	737,813

GAAP Operating Income		60,403	14.4	%		46,880	12.3	%		104,560	13.1	%		87,913	11.9	%
Cost of Sales
Amortization of intangibles		18,718	4.5	%		18,980	5.0	%		36,945	4.6	%		36,586	5.0	%
Inventory mark-up related to acquisitions		—	—			67	0.0	%		—	—			67	0.0	%
Operating Expenses
Contingent consideration expense (benefit)		145	0.0	%		143	0.0	%		(34)	(0.0)	%		1,166	0.2	%
Amortization of intangibles		2,496	0.6	%		2,543	0.7	%		4,950	0.6	%		4,937	0.7	%
Performance-based share-based compensation (a)		6,621	1.6	%		5,879	1.5	%		12,429	1.6	%		10,653	1.4	%
Corporate restructuring (b)		2,159	0.5	%		2,587	0.7	%		2,159	0.3	%		2,587	0.4	%
Acquisition-related		2,568	0.6	%		2,140	0.6	%		6,811	0.9	%		2,156	0.3	%
Medical Device Regulation expenses (c)		1,452	0.3	%		1,634	0.4	%		2,070	0.3	%		3,228	0.4	%
Other (d)		—	—			50	0.0	%		—	—			29	0.0	%

Non-GAAP Operating Income	$	94,562	22.6	%	$	80,903	21.2	%	$	169,890	21.2	%	$	149,322	20.2	%

Note: Certain percentages may not sum to totals due to rounding.

(a)	Represents performance-based share-based compensation expense, including stock-settled and cash-settled awards.

(b)	Includes employee termination benefits associated with activities related to corporate restructuring initiatives and costs to terminate certain distribution contracts from the Biolife Merger.

(c)	Represents incremental expenses incurred to comply with the E.U. Medical Device Regulation.

(d)	Represents costs to comply with Merit’s corporate integrity agreement with the U.S. Department of Justice.

(e)	Represents costs associated with the Convertible Notes including the amortization of debt issuance costs and a one-time charge for additional interest incurred pursuant to Merit's obligation to remove restrictive legends.

(f)	Includes equity method investment loss from equity investees.

Reconciliation of Reported Revenue to Constant Currency Revenue (Non-GAAP), and Constant Currency Revenue, Organic (Non-GAAP)

(Unaudited, in thousands except percentages)


			Three Months Ended						Six Months Ended
			June 30,						June 30,
	% Change		2026		2025		% Change		2026		2025
Reported Revenue	9.5	%	$	418,843	$	382,462	8.5	%	$	800,720	$	737,813

Add: Impact of foreign exchange				(2,987)		—				(10,923)		—

Constant Currency Revenue (a)	8.7	%	$	415,856	$	382,462	7.0	%	$	789,797	$	737,813

Less: Revenue from certain acquisitions				(4,660)		—				(13,704)		—
Less: Revenue from divestitures (b)				—		(5,296)				(1,644)		(10,212)

Constant Currency Revenue, Organic (a)	9.0	%	$	411,196	$	377,166	6.4	%	$	774,449	$	727,601

(a)	A non-GAAP financial measure. For a definition of this and other non-GAAP financial measures, see the section of this release entitled “Non-GAAP Financial Measures.”

(b)	On February 17, 2026, Merit sold certain assets relating to the DualCap product line to Health Line for $28 million, of which $25.5 million was paid to Merit at closing.

Reconciliation of Reported Gross Margin to Non-GAAP Gross Margin (Non-GAAP)

(Unaudited, as a percentage of reported revenue)


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2026		2025		2026		2025
Reported Gross Margin	51.4	%	48.2	%	50.0	%	48.3	%

Add back impact of:
Amortization of intangibles	4.5	%	5.0	%	4.6	%	5.0	%
Inventory mark-up related to acquisitions	—	%	0.0	%	—	%	0.0	%

Non-GAAP Gross Margin	55.8	%	53.2	%	54.6	%	53.3	%

Note: Certain percentages may not sum to totals due to rounding.

Reconciliation of Reported Cash Flow from Operations to Free Cash Flow (Non-GAAP)

(Unaudited, in thousands)


	Six Months Ended
	June 30,
	2026		2025
Reported Cash Flow from Operations	$	109,957	$	123,879

Less: Capital Expenditures		(33,340)		(34,812)

Free Cash Flow	$	76,617	$	89,067

Reconciliation of 2026 Net Sales Guidance - % Change from Prior Year (Constant Currency)


	Updated Guidance		Prior Guidance⁽¹⁾
	Low	High	Low	High
2026 Net Sales Guidance - % Change from Prior Year (GAAP)	7.6%	8.4%	6.3%	7.8%
Estimated impact of foreign currency exchange rate fluctuations	(0.8%)	(0.8%)	(0.8%)	(0.8%)
2026 Net Sales Guidance - % Change from Prior Year (Constant Currency)	6.8%	7.6%	5.6%	7.0%

Note: Certain percentages may not sum to totals due to rounding.

(1) “Prior Guidance” reflects Merit’s full-year 2026 financial guidance, previously introduced on April 30, 2026.

ABOUT MERIT

Founded in 1987, Merit is engaged in the development, manufacture, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves customers worldwide with a domestic and international sales force and clinical support team totaling more than 800 individuals. Merit employs approximately 7,500 people worldwide.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among others:

●

statements preceded or followed by, or that include the words, “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “intends,” “seeks,” “believes,” “estimates,” “projects,” “forecasts,” “potential,” “target,” “continue,” “upcoming,” “optimistic” or other forms of these words or similar words or expressions, or the negative thereof or other comparable terminology;

●

statements that address Merit’s future operating performance or events or developments that Merit’s management expects or anticipates will occur, including, without limitation, any statements regarding Merit’s projected revenues, earnings or other future financial measures, Merit’s plans and objectives for future operations, Merit’s proposed new products or services, the integration, development or commercialization of the business or any assets acquired from other parties, future economic conditions or performance, the implementation of, and results which may be achieved through, Merit’s Continued Growth Initiatives Program or other business optimization initiatives, and any statements of assumptions underlying any of the foregoing; and

●

statements regarding Merit’s past performance, efforts, or results about which inferences or assumptions may be made, including statements proceeded or followed by the words "preliminary," "initial," "potential," "possible," "diligence," "industry-leading," "compliant," "indications" or "early feedback" or other forms of these words or similar words or expressions, or the negative thereof or other comparable terminology.

The forward-looking statements contained in this release are based on Merit management’s current expectations and assumptions regarding future events or outcomes. If underlying expectations or assumptions prove inaccurate, or risks or uncertainties materialize, actual results will likely differ, and may differ materially, from Merit’s expectations reflected in any forward-looking statements. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results. Investors are cautioned not to unduly rely on any such forward-looking statements.

The following are some of the important risks and uncertainties that could cause Merit’s actual results to differ from management’s expectations in any forward-looking statements: risks and uncertainties arising from the conflict among the United States, Israel and Iran and related geopolitical instability; risks and uncertainties associated with Merit’s acquisition of View Point and the OneMark® Detection Imaging System and related technology; risks and uncertainties associated with Merit’s integration of the View Point business, assets and operations into its operations and its ability to achieve anticipated financial results, product development and other anticipated benefits of the acquisition; uncertainties as to whether Merit will achieve revenue or other financial performance consistent with its forecasts projected for the View Point Merger; risks and uncertainties associated with Merit’s executive succession planning activities and leadership transition; risks and uncertainties regarding trade policies or related actions implemented by the U.S. or other countries, including existing, proposed, prospective or invalidated tariffs, duties or other measures; risks and uncertainties associated with Merit’s integration of businesses or assets acquired from third parties, including View Point in April 2026, the business and assets acquired in the C2 Acquisition in November 2025 and Biolife in May 2025, and Merit’s ability to achieve the anticipated financial results, product development and other anticipated benefits of such acquisitions; effects of the Convertible Notes on Merit’s net income and earnings per share performance; restrictions and limitations set forth in the Convertible Notes and Indenture, which could affect Merit’s ability to operate its business as well as its liquidity; disruptions in Merit’s supply chain, manufacturing or sterilization processes; U.S. and global political, economic, competitive, reimbursement and regulatory conditions; modification or limitation of, or policies and procedures associated with, governmental or private insurance reimbursement policies; reduced availability of, and price increases associated with, components and other raw materials; increases in transportation expenses; risks relating to Merit’s potential inability to successfully manage growth through acquisitions generally, including the inability to effectively integrate acquired operations or products or commercialize technology developed internally or acquired through completed, proposed or future transactions; prospective financial obligations or other uncertainties associated with the DualCap Divestiture completed in February 2026; fluctuations in interest or foreign currency exchange rates and inflation; cybersecurity

events; government scrutiny and regulation of the medical device industry; difficulties relating to development, testing and regulatory approval, clearance and maintenance of Merit’s products; the safety, efficacy and patient and physician adoption of Merit’s products; the ability to fully enroll and the outcomes of ongoing and future clinical trials and market studies relating to Merit’s products; litigation and other legal proceedings affecting Merit; risks and possible effects of Merit’s failure to comply with U.S. and foreign laws and regulations; restrictions on Merit’s liquidity or business operations resulting from its debt agreements; infringement of Merit’s technology or the assertion that Merit’s technology infringes the rights of other parties; product recalls and product liability claims; potential for significant adverse changes in governing regulations; changes in tax laws and regulations in the United States or other jurisdictions or exposure to additional tax liabilities which may adversely affect Merit’s effective tax rate; termination of relationships with Merit’s suppliers, or failure of such suppliers to perform; development of new products and technology that could render Merit’s existing or future products obsolete; market acceptance of new products; failure to comply with applicable environmental laws; changes in key personnel; labor shortages and increases in labor costs; price and product competition; extreme weather events; and geopolitical events. For a further discussion of the risks and uncertainties and other factors that may affect Merit’s business, operations and financial condition, see Part I, Item 1A. “Risk Factors” in Merit’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC, which Merit updated in Part II, Item 1A. “Risk Factors” in Merit’s Quarterly Reports on Form 10-Q for each of the quarters ended March 31, 2026 and June 30, 2026.

All subsequent forward-looking statements attributable to Merit or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Actual results will likely differ, and may differ materially, from anticipated results. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results. Those estimates and all other forward-looking statements included in this release are made only as of the date of this release, and except as otherwise required by applicable law, Merit assumes no obligation to update or disclose revisions to estimates and all other forward-looking statements.

TRADEMARKS

Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc., its subsidiaries, or its licensors.

# # #

Exhibit 99.2

1 Merit Medical Investor Call July 30, 2026 Second Quarter 2026 Results Martha Aronson President and CEO Raul Parra CFO

2 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among others:  statements preceded or followed by, or that include the words, “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “intends,” “seeks,” “believes,” “estimates,” “projects,” “forecasts,” “potential,” “target,” “continue,” “upcoming,” “optimistic” or other forms of these words or similar words or expressions, or the negative thereof or other comparable terminology;  statements that address Merit’s future operating performance or events or developments that Merit’s management expects or anticipates will occur, including, without limitation, any statements regarding Merit’s projected revenues, earnings or other future financial measures, Merit’s plans and objectives for future operations, Merit’s proposed new products or services, the integration, development or commercialization of the business or any assets acquired from other parties, future economic conditions or performance, the implementation of, and results which may be achieved through, Merit’s Continued Growth Initiatives Program or other business optimization initiatives, and any statements of assumptions underlying any of the foregoing; and  statements regarding Merit’s past performance, efforts, or results about which inferences or assumptions may be made, including statements proceeded or followed by the words "preliminary," "initial," "potential," "possible," "diligence," "industry-leading," "compliant," "indications," or "early feedback" or other forms of these words or similar words or expressions, or the negative thereof or other comparable terminology. The forward-looking statements contained in this presentation are based on Merit management’s current expectations and assumptions regarding future events or outcomes. If underlying expectations or assumptions prove inaccurate, or risks or uncertainties materialize, actual results will likely differ, and may differ materially, from Merit’s expectations reflected in any forward-looking statements. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results. Investors are cautioned not to unduly rely on any such forward-looking statements. The following are some of the important risks and uncertainties that could cause Merit’s actual results to differ from management’s expectations in any forward-looking statements: risks and uncertainties arising from the conflict among the United States, Israel and Iran and related geopolitical instability; risks and uncertainties associated with Merit’s acquisition of View Point Medical, Inc. (“View Point”) and the OneMark® Detection Imaging System and related technology; risks and uncertainties associated with Merit’s integration of the View Point business, assets and operations into its operations and its ability to achieve anticipated financial results, product development and other anticipated benefits of the acquisition; uncertainties as to whether Merit will achieve revenue or other financial performance consistent with its forecasts projected for Merit’s acquisition of View Point in April 2026 (the “View Point Merger”); risks and uncertainties associated with Merit’s executive succession planning activities and leadership transition; risks and uncertainties regarding trade policies or related actions implemented by the U.S. or other countries, including existing, proposed, prospective or invalidated tariffs, duties or other measures; risks and uncertainties associated with Merit’s integration of businesses or assets acquired from third parties, including View Point in April 2026, the business and assets acquired from Pentax of America, Inc. related to the C2 CryoBalloon device in November 2025 (the “C2 Acquisition”) and Merit’s acquisition of Biolife Delaware, L.L.C. (“Biolife”) in May 2025 (the “Biolife Merger”), and Merit’s ability to achieve the anticipated financial results, product development and other anticipated benefits of such acquisitions; effects of the Convertible Notes on Merit’s net income and earnings per share performance; restrictions and limitations set forth in the Convertible Notes and Indenture, which could affect Merit’s ability to operate its business as well as its liquidity; disruptions in Merit’s supply chain, manufacturing or sterilization processes; U.S. and global political, economic, competitive, reimbursement and regulatory conditions; modification or limitation of, or policies and procedures associated with, governmental or private insurance reimbursement policies; reduced availability of, and price increases associated with, components and other raw materials; increases in transportation expenses; risks relating to Merit’s potential inability to successfully manage growth through acquisitions generally, including the inability to effectively integrate acquired operations or products or commercialize technology developed internally or acquired through completed, proposed or future transactions; prospective financial obligations or other uncertainties associated with the DualCap® product line which Merit sold to Health Line International Corporation (“Health Line”) on February 17, 2026 (the “DualCap Divestiture”); fluctuations in interest or foreign currency exchange rates and inflation; cybersecurity events; government scrutiny and regulation of the medical device industry; difficulties relating to development, testing and regulatory approval, clearance and maintenance of Merit’s products; the safety, efficacy and patient and physician adoption of Merit’s products; the ability to fully enroll and the outcomes of ongoing and future clinical trials and market studies relating to Merit’s products; litigation and other legal proceedings affecting Merit; risks and possible effects of Merit’s failure to comply with U.S. and foreign laws and regulations; restrictions on Merit’s liquidity or business operations resulting from its debt agreements; infringement of Merit’s technology or the assertion that Merit’s technology infringes the rights of other parties; product recalls and product liability claims; potential for significant adverse changes in governing regulations; changes in tax laws and regulations in the United States or other jurisdictions or exposure to additional tax liabilities which may adversely affect Merit’s effective tax rate; termination of relationships with Merit’s suppliers, or failure of such suppliers to perform; development of new products and technology that could render Merit’s existing or future products obsolete; market acceptance of new products; failure to comply with applicable environmental laws; changes in key personnel; labor shortages and increases in labor costs; price and product competition; extreme weather events; and geopolitical events. For a further discussion of the risks and uncertainties and other factors that may affect Merit’s business, operations and financial condition, see Part I, Item 1A. “Risk Factors” in Merit’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC, which Merit updated in Part II, Item 1A. “Risk Factors” in Merit’s Quarterly Reports on Form 10-Q for each of the quarters ended March 31, 2026 and June 30, 2026. All subsequent forward-looking statements attributable to Merit or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Actual results will likely differ, and may differ materially, from anticipated results. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results. Those estimates and all other forward-looking statements included in this presentation are made only as of the date of this presentation, and except as otherwise required by applicable law, Merit assumes no obligation to update or disclose revisions to estimates and all other forward-looking statements.

3 NON-GAAP FINANCIAL MEASURES Although Merit’s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”), Merit’s management believes that certain non-GAAP financial measures provide investors with useful information regarding the underlying business trends and performance of Merit’s ongoing operations and can be useful for period-over-period comparisons of such operations. Certain financial measures included in this presentation, or which may be referenced in management’s discussion of Merit’s historical and future operations and financial results, have not been calculated in accordance with GAAP, and, therefore, are referenced as non-GAAP financial measures. Readers should consider non-GAAP measures used in this presentation in addition to, not as a substitute for, financial reporting measures prepared in accordance with GAAP. These non-GAAP financial measures generally exclude some, but not all, items that may affect Merit's net income. In addition, they are subject to inherent limitations as they reflect the exercise of judgment by management about which items are excluded. Additionally, non-GAAP financial measures used in this presentation may not be comparable with similarly titled measures of other companies. Merit urges readers to review the reconciliations of its non-GAAP financial measures to the comparable GAAP financial measures, and not to rely on any single financial measure to evaluate Merit’s business or results of operations. Please refer to “Notes to Non-GAAP Financial Measures” at the end of these materials for more information. TRADEMARKS Unless noted otherwise, trademarks and registered trademarks used in this presentation are the property of Merit Medical Systems, Inc., its subsidiaries, or its licensors.

4 Q2 2026 Q2 2025 % Change YTD 2026 YTD 2025 % Change Revenue $418.8M $382.5M 9.5% $800.7M $737.8M 8.5% Gross Margin 51.4% 48.2% 6.5% 50.0% 48.3% 3.4% Operating Margin 14.4% 12.3% 17.7% 13.1% 11.9% 9.6% Net Income $38.8M $32.6M 19.1% $79.8M $62.7M 27.2% Earnings per Share $0.65 $0.54 20.3% $1.33 $1.03 29.2% Financial Summary: GAAP 4 Note: Amounts in this presentation are rounded while percentages are calculated from the underlying amounts. In millions, except per share amounts and percentages

5 Q2 2026 Q2 2025 % Change YTD 2026 YTD 2025 % Change $411.2M $377.2M 9.0% $774.4M $727.6M 6.4% Constant Currency Revenue, Organic* Non-GAAP Gross Margin* 55.8% 53.2% 4.9% 54.6% 53.3% 2.4% Non-GAAP Operating Margin* 22.6% 21.2% 6.7% 21.2% 20.2% 4.8% Non-GAAP Net Income* $71.3M $61.0M 16.9% $127.9M $113.9M 12.3% Non-GAAP Earnings per Share* $1.19 $1.01 18.0% $2.13 $1.87 14.1% Financial Summary: Non-GAAP* 5 Note: Amounts in this presentation are rounded while percentages are calculated from the underlying amounts. * See "Notes to Non-GAAP Financial Measures" below for additional information regarding non-GAAP measures used in this presentation. In millions, except per share amounts and percentages

6 Revenue Breakdown – Q2 Region Q2 2026 Q2 2025 $ Change % Change CC % Change* Domestic $252,051 $227,082 $24,969 11.0% 11.5% International 166,792 155,380 11,412 7.3% 4.7% Total $418,843 $382,462 $36,381 9.5% 8.7% 6 * A non-GAAP financial measure, representing revenue growth on a constant currency (“CC”) basis. See "Notes to Non-GAAP Financial Measures" below for additional information regarding non-GAAP measures used in this presentation. In thousands, except percentages

7 Revenue Breakdown - YTD * A non-GAAP financial measure, representing revenue growth on a constant currency (“CC”) basis. See "Notes to Non-GAAP Financial Measures" below for additional information regarding non-GAAP measures used in this presentation. In thousands, except percentages Region YTD 2026 YTD 2025 $ Change % Change CC % Change* Domestic $478,567 $440,646 $37,921 8.6% 9.2% International 322,153 297,167 24,986 8.4% 3.8% Total $800,720 $737,813 $62,907 8.5% 7.0%

8 Financial Metrics Metric Q2 2026 Q2 2025 YTD 2026 YTD 2025 Depreciation & Amortization $31.0M $31.0M $61.5M $60.3M Stock Comp (performance-based) 6.6M 5.9M 12.4M 10.7M Stock Comp (not performance-based) 6.3M 5.0M 9.5M 9.3M Operating Cash Flow 69.3M 83.3M 110.0M 123.9M Capital Expenditures-Property and Equipment 17.3M 13.8M 33.3M 34.8M 8 In millions

9 Fiscal Year 2026 Financial Guidance Merit does not provide guidance for GAAP reported financial measures (other than revenue) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures (other than revenue) because Merit is unable to predict with reasonable certainty the financial impact of various items which could impact Merit’s future financial results, such as expenses related to acquisitions or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain employee termination benefits, performance-based stock compensation expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings, and changes in governmental or industry regulations. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For the same reasons, Merit is unable to address the significance of the unavailable information, which could be material to future results. Specifically, Merit is not, without unreasonable effort, able to reasonably predict the amount and impact of these items and Merit believes inclusion of the most comparable GAAP financial measure, and a reconciliation of these forward-looking non-GAAP measures to their GAAP counterparts could be confusing to investors or cause undue reliance. Merit’s financial guidance for the year ending December 31, 2026, is subject to risks and uncertainties identified in this presentation and Merit’s filings with the U.S. Securities and Exchange Commission (the “SEC”). This guidance is based on information and estimates available to Merit as of July 30, 2026. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results will likely vary, and could vary materially, from past results and those anticipated, estimated or projected. (1) “Prior Guidance” reflects Merit’s full-year 2026 financial guidance, previously introduced on April 30, 2026. * Percentage figures approximated; percentage and dollar figures may not foot due to rounding 2026 Net Sales Guidance - % Change from Prior Year (Constant Currency) Reconciliation* Revenue and Earnings Guidance* (1) Merit’s non-GAAP earnings per share reflect the dilutive impact of its 3.00% Convertible Senior Notes due 2029 calculated using the if-converted method of approximately $0.03 per share for the year ending December 31, 2026. Any offsetting impacts of the capped call associated with the Convertible Notes are not considered. (2) “Prior Guidance” reflects Merit’s full-year 2026 financial guidance, previously introduced on April 30, 2026. Year Ending % Change Year Ending % Change Financial Measure December 31, 2026 Y/Y December 31, 2026 Y/Y Total Revenue $1.631 - $1.643 billion 8% - 8% $1.612 - $1.634 billion 6% - 8% Non-GAAP Earnings Per Share(1) $4.25 - $4.35 11% - 14% $4.01 - $4.15 5% - 8% Updated Guidance Prior Guidance(2) Low High Low High 2026 Net Sales Guidance - % Change from Prior Year (GAAP) 7.6% 8.4% 6.3% 7.8% Estimated impact of foreign currency exchange rate fluctuations (0.8%) (0.8%) (0.8%) (0.8%) 2026 Net Sales Guidance - % Change from Prior Year (Constant Currency) 6.8% 7.6% 5.6% 7.0% Updated Guidance Prior Guidance(1)

10 Appendix

11 Notes to Non-GAAP Financial Measures For additional details, please see the accompanying press release and forward-looking statement disclosure. These presentation materials and associated commentary from Merit’s management, as well as the press release issued today, use non-GAAP financial measures, including: • constant currency revenue; • constant currency revenue, organic; • non-GAAP gross profit and margin; • non-GAAP operating income and margin; • non-GAAP net income; • non-GAAP earnings per share; and • free cash flow. Merit’s management team uses these non-GAAP financial measures to evaluate Merit’s profitability and efficiency, to compare operating and financial results to prior periods, to evaluate changes in the results of its operating segments, and to measure and allocate financial resources internally. However, Merit’s management does not consider such non-GAAP measures in isolation or as an alternative to measures determined in accordance with GAAP. Readers should consider non-GAAP measures used in this presentation in addition to, not as a substitute for, financial reporting measures prepared in accordance with GAAP. These non-GAAP financial measures generally exclude some, but not all, items that may affect Merit’s net income. In addition, they are subject to inherent limitations as they reflect the exercise of judgment by management about which items are excluded. Merit believes it is useful to exclude such items in the calculation of non-GAAP gross profit and margin, non-GAAP operating income and margin, non-GAAP net income, and non-GAAP earnings per share (in each case, as further illustrated in the reconciliation tables below) because such amounts in any specific period may not directly correlate to the underlying performance of Merit’s business operations and can vary significantly between periods as a result of factors such as acquisition or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain employee termination benefits, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings or changes in tax or industry regulations, gains or losses on disposal of certain assets, equity method investment loss (income) from equity investees, and debt issuance costs. Merit may incur similar types of expenses in the future, and the non-GAAP financial information included in this presentation should not be viewed as a statement or indication that these types of expenses will not recur. Additionally, the non-GAAP financial measures used in this presentation may not be comparable with similarly titled measures of other companies. Merit urges readers to review the reconciliations of its non-GAAP financial measures to their most directly comparable GAAP financial measures included herein, and not to rely on any single financial measure to evaluate Merit’s business or results of operations.

12 Notes to Non-GAAP Financial Measures (cont.) Constant Currency Revenue Merit’s constant currency revenue is prepared by converting the current-period reported revenue of subsidiaries whose functional currency is a currency other than the U.S. dollar at the applicable foreign exchange rates in effect during the comparable prior-year period and adjusting for the effects of hedging transactions on reported revenue, which are recorded in the U.S. dollar. The constant currency revenue adjustment of $(3.0) million and $(10.9) million to reported revenue for the three and six-month periods ended June 30, 2026 was calculated using the applicable average foreign exchange rates for the three and six-month periods ended June 30, 2025. Constant Currency Revenue, Organic Merit’s constant currency revenue, organic, is defined, with respect to prior fiscal year periods, as GAAP revenue less revenue from certain divestitures. For the three and six-month periods ended June 30, 2025, Merit’s constant currency revenue, organic, excludes revenues attributable to the DualCap Divestiture. With respect to current fiscal year periods, constant currency revenue, organic, is defined as constant currency revenue (as defined above), less revenue from certain acquisitions and divestitures. For the three and six-month periods ended June 30, 2026, Merit’s constant currency revenue, organic, excludes revenues attributable to products acquired in connection with (i) the View Point Merger, (ii) the C2 Acquisition and (iii) the Biolife Merger. For the six-month period ended June 30, 2026, Merit’s constant currency revenue, organic, excludes revenues attributable to the DualCap Divestiture. Non-GAAP Gross Profit and Margin Non-GAAP gross profit is calculated by reducing GAAP cost of sales by amounts recorded for amortization of intangible assets and inventory mark-up related to acquisitions. Non-GAAP gross margin is calculated by dividing non-GAAP gross profit by reported net sales. Non-GAAP Operating Income and Margin Non-GAAP operating income is calculated by adjusting GAAP operating income for certain items which are deemed by Merit’s management to be outside of core operations and vary in amount and frequency among periods, such as expenses related to acquisitions or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain employee termination benefits, performance-based stock compensation expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings, and changes in governmental or industry regulations, as well as other items referenced in the tables below. Non-GAAP operating margin is calculated by dividing non-GAAP operating income by reported net sales.

13 Notes to Non-GAAP Financial Measures (cont.) Non-GAAP Net Income Non-GAAP net income is calculated by adjusting GAAP net income for the items set forth in the definition of non-GAAP operating income above, as well as for expenses related to our long-term debt, gains or losses on disposal of certain assets, equity method investment loss (income) from equity investees, and other items set forth in the tables below. Non-GAAP EPS Non-GAAP EPS is defined as non-GAAP net income divided by the diluted shares outstanding for the corresponding period. Free Cash Flow Free cash flow is defined as cash flow from operations calculated in accordance with GAAP, less capital expenditures for property and equipment calculated in accordance with GAAP, as set forth in the consolidated statement of cash flows. Other Non-GAAP Financial Measure Reconciliations The following tables set forth supplemental financial data and corresponding reconciliations of non-GAAP financial measures to Merit’s corresponding financial measures prepared in accordance with GAAP, in each case, for the three and six-month periods ended June 30, 2026 and 2025. The non-GAAP income adjustments referenced in the following tables do not reflect non-performance-based stock compensation expense of $6.3 million and $5.0 million for the three-month periods ended June 30, 2026 and 2025, respectively, and $9.5 million and $9.3 million for the six-month periods ended June 30, 2026 and 2025, respectively.

14 Reconciliation of GAAP Net Income to Non-GAAP Net Income (Unaudited; in thousands except per share amounts) Note: Certain per-share impacts may not sum to totals due to rounding. GAAP net income $ 51,314 $ (12,511) $ 38,803 $ 0.65 $ 43,379 $ (10,798) $ 32,581 $ 0.54 Non-GAAP adjustments: Cost of Sales Amortization of intangibles 18,718 (4,419) 14,299 0.24 18,980 (4,485) 14,495 0.24 Inventory mark-up related to acquisitions — — — — 67 (16) 51 0.00 Operating Expenses Contingent consideration expense 145 (33) 112 0.00 143 25 168 0.00 Amortization of intangibles 2,496 (589) 1,907 0.03 2,543 (601) 1,942 0.03 Performance-based share-based compensation (a) 6,621 (756) 5,865 0.10 5,879 (345) 5,534 0.09 Corporate restructuring (b) 2,159 (510) 1,649 0.03 2,587 (611) 1,976 0.03 Acquisition-related 2,568 (194) 2,374 0.04 2,140 (14) 2,126 0.04 Medical Device Regulation expenses (c) 1,452 (342) 1,110 0.02 1,634 (385) 1,249 0.02 Other (d) — — — — 50 (12) 38 0.00 Other (Income) Expense Long-term debt costs (e) 6,477 (1,529) 4,948 0.08 1,414 (334) 1,080 0.02 Gain on disposal of business unit — — — — (249) — (249) (0.00) Other non-operating loss (f) 294 (82) 212 0.00 — — — — Non-GAAP net income $ 92,244 $ (20,965) $ 71,279 $ 1.19 $ 78,567 $ (17,576) $ 60,991 $ 1.01 Diluted shares 60,006 60,611 Pre-Tax Tax Impact After-Tax Per Share Impact Pre-Tax Tax Impact After-Tax Per Share Impact Three Months Ended Three Months Ended June 30, 2026 June 30, 2025

15 Reconciliation of GAAP Net Income to Non-GAAP Net Income (Unaudited; in thousands except per share amounts) Note: Certain per-share impacts may not sum to totals due to rounding. GAAP net income $ 104,860 $ (25,062) $ 79,798 $ 1.33 $ 81,337 $ (18,609) $ 62,728 $ 1.03 Non-GAAP adjustments: Cost of Sales Amortization of intangibles 36,945 (8,722) 28,223 0.47 36,586 (8,645) 27,941 0.46 Inventory mark-up related to acquisitions — — — — 67 (16) 51 0.00 Operating Expenses Contingent consideration (benefit) expense (34) 5 (29) (0.00) 1,166 34 1,200 0.02 Amortization of intangibles 4,950 (1,168) 3,782 0.06 4,937 (1,167) 3,770 0.06 Performance-based share-based compensation (a) 12,429 (1,062) 11,367 0.19 10,653 (931) 9,722 0.16 Corporate restructuring (b) 2,159 (510) 1,649 0.03 2,587 (611) 1,976 0.03 Acquisition-related 6,811 (905) 5,906 0.10 2,156 (18) 2,138 0.04 Medical Device Regulation expenses (c) 2,070 (488) 1,582 0.03 3,228 (762) 2,466 0.04 Other (d) — — — — 29 (7) 22 0.00 Other (Income) Expense Long-term debt costs (e) 7,891 (1,863) 6,028 0.10 2,828 (668) 2,160 0.04 Gain on disposal of business unit (12,502) 1,520 (10,982) (0.18) (249) — (249) (0.00) Other non-operating loss (f) 825 (207) 618 0.01 — — — — Non-GAAP net income $ 166,404 $ (38,462) $ 127,942 $ 2.13 $ 145,325 $ (31,400) $ 113,925 $ 1.87 Diluted shares 60,010 60,945 Pre-Tax Tax Impact After-Tax Per Share Impact Pre-Tax Tax Impact After-Tax Per Share Impact Six Months Ended Six Months Ended June 30, 2026 June 30, 2025

16 Reconciliation of GAAP Operating Income to Non-GAAP Operating Income (Unaudited; in thousands except percentages) Note: Certain percentages may not sum to totals due to rounding. Net Sales as Reported $ 418,843 $ 382,462 $ 800,720 $ 737,813 GAAP Operating Income 60,403 14.4 % 46,880 12.3 % 104,560 13.1 % 87,913 11.9 % Cost of Sales Amortization of intangibles 18,718 4.5 % 18,980 5.0 % 36,945 4.6 % 36,586 5.0 % Inventory mark-up related to acquisitions — — 67 0.0 % — — 67 0.0 % Operating Expenses Contingent consideration expense (benefit) 145 0.0 % 143 0.0 % (34) (0.0) % 1,166 0.2 % Amortization of intangibles 2,496 0.6 % 2,543 0.7 % 4,950 0.6 % 4,937 0.7 % Performance-based share-based compensation (a) 6,621 1.6 % 5,879 1.5 % 12,429 1.6 % 10,653 1.4 % Corporate restructuring (b) 2,159 0.5 % 2,587 0.7 % 2,159 0.3 % 2,587 0.4 % Acquisition-related 2,568 0.6 % 2,140 0.6 % 6,811 0.9 % 2,156 0.3 % Medical Device Regulation expenses (c) 1,452 0.3 % 1,634 0.4 % 2,070 0.3 % 3,228 0.4 % Other (d) — — 50 0.0 % — — 29 0.0 % Non-GAAP Operating Income $ 94,562 22.6 % $ 80,903 21.2 % $ 169,890 21.2 % $ 149,322 20.2 % Amounts % Sales Amounts % Sales Amounts % Sales Amounts % Sales Three Months Ended Three Months Ended Six Months Ended Six Months Ended June 30, 2026 June 30, 2025 June 30, 2026 June 30, 2025

17 Footnotes to Reconciliations of GAAP Net Income to Non-GAAP Net Income and GAAP Operating Income to Non-GAAP Operating Income a) Represents performance-based share-based compensation expense, including stock-settled and cash-settled awards. b) Includes employee termination benefits associated with activities related to corporate restructuring initiatives and costs to terminate certain distribution contracts from our Biolife Merger. c) Represents incremental expenses incurred to comply with the E.U. Medical Device Regulation. d) Represents costs to comply with Merit’s corporate integrity agreement with the U.S. Department of Justice. e) Represents costs associated with our Convertible Notes including the amortization of debt issuance costs and a one-time charge for additional interest incurred pursuant to Merit's obligation to remove restrictive legends. f) Includes equity method investment loss from equity investees.

18 Reconciliation of Reported Revenue to Constant Currency Revenue (Non-GAAP), and Constant Currency Revenue, Organic (Non-GAAP) (Unaudited; in thousands except percentages) (a) A non-GAAP financial measure. For a definition of this and other non-GAAP financial measures, see the section of this presentation entitled “Notes to Non-GAAP Financial Measures.” (b) On February 17, 2026, Merit sold certain assets relating to the DualCap product line to Health Line for $28 million, of which $25.5 million was paid to Merit at closing. % Change % Change Reported Revenue 9.5 % $ 418,843 $ 382,462 8.5 % $ 800,720 $ 737,813 Add: Impact of foreign exchange (2,987) — (10,923) — Constant Currency Revenue (a) 8.7 % $ 415,856 $ 382,462 7.0 % $ 789,797 $ 737,813 Less: Revenue from certain acquisitions — (4,660) (13,704) — Less: Revenue from divestitures (b) (5,296) — (1,644) (10,212) Constant Currency Revenue, Organic (a) 9.0 % $ 411,196 $ 377,166 6.4 % $ 774,449 $ 727,601 Three Months Ended Six Months Ended June 30, June 30, 2026 2025 2026 2025

19 Reconciliation of GAAP Gross Margin to Non-GAAP Gross Margin (Unaudited; as a percentage of reported revenue) Note: Certain percentages may not sum to totals due to rounding. 2026 2025 2026 2025 Reported Gross Margin 51.4 % 48.2 % 50.0 % 48.3 % Add back impact of: Amortization of intangibles 4.5 % 5.0 % 4.6 % 5.0 % Inventory mark-up related to acquisitions — % 0.0 % — % 0.0 % Non-GAAP Gross Margin % 53.2 55.8 % 54.6 % 53.3 % June 30, Three Months Ended Six Months Ended June 30,

20 Reconciliation of Reported Cash Flow from Operations to Free Cash Flow (Unaudited; in thousands) Reported Cash Flow from Operations $ 109,957 $ 123,879 Less: Capital Expenditures (34,812) (33,340) Free Cash Flow $ 76,617 $ 89,067 Six Months Ended June 30, 2026 2025

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

5 documents

Merit Medical (NASDAQ: MMSI) boosts 2026 outlook after strong Q2 results

Rhea-AI Filing Summary

Positive

Negative

Filing Explained

8-K Event Classification

Key Figures

Key Terms

Earnings Snapshot

FAQ

How did Merit Medical (MMSI) perform in Q2 2026?

What guidance did Merit Medical (MMSI) provide for full-year 2026?

What is Merit Medical’s (MMSI) cash and debt position as of June 30, 2026?

How does Merit Medical (MMSI) use non-GAAP financial measures?

What drove Merit Medical’s (MMSI) revenue growth by category in Q2 2026?

How did acquisitions and divestitures affect Merit Medical’s (MMSI) organic growth?

Filing Exhibits & Attachments

Press Releases

Other Documents